Beta Bionics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 21/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 31.30.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beta Bionics Inc's Score
Industry at a Glance
Industry Ranking
21 / 207
Overall Ranking
93 / 4563
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Buy
Current Rating
31.300
Target Price
+10.56%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Beta Bionics Inc Highlights
StrengthsRisks
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 36282.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 65.12M.
Undervalued
The company’s latest PE is -16.40, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 48.60M shares, increasing 0.09% quarter-over-quarter.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Ticker SymbolBBNX
CompanyBeta Bionics Inc
CEOSaint (Sean)
Websitehttps://www.betabionics.com
FAQs
What is the current price of Beta Bionics Inc (BBNX)?
The current price of Beta Bionics Inc (BBNX) is 31.860.
What is the symbol of Beta Bionics Inc?
The ticker symbol of Beta Bionics Inc is BBNX.
What is the 52-week high of Beta Bionics Inc?
The 52-week high of Beta Bionics Inc is 32.710.
What is the 52-week low of Beta Bionics Inc?
The 52-week low of Beta Bionics Inc is 8.890.
What is the market capitalization of Beta Bionics Inc?
The market capitalization of Beta Bionics Inc is 1.40B.
What is the net income of Beta Bionics Inc?
The net income of Beta Bionics Inc is -54.76M.
Is Beta Bionics Inc (BBNX) currently rated as Buy, Hold, or Sell?
According to analysts, Beta Bionics Inc (BBNX) has an overall rating of Buy, with a price target of 31.300.
What is the Earnings Per Share (EPS TTM) of Beta Bionics Inc (BBNX)?
The Earnings Per Share (EPS TTM) of Beta Bionics Inc (BBNX) is -1.943.